Introduction of Chinese expert consensus on neoadjuvant therapy for primary liver cancer (2023 edition)

Jizhou Wang; Lianxin Liu

doi:10.20517/2394-5079.2024.33

Hepatoma Research ›› 2024, Vol. 10:10 DOI: 10.20517/2394-5079.2024.33

Editorial

Introduction of Chinese expert consensus on neoadjuvant therapy for primary liver cancer (2023 edition)

Jizhou Wang ¹^,²^,³
, Lianxin Liu ¹^,²^,³

Author information +

History +

PDF

Cite this article

Download citation ▾

Jizhou Wang, Lianxin Liu. Introduction of Chinese expert consensus on neoadjuvant therapy for primary liver cancer (2023 edition). Hepatoma Research, 2024, 10: 10 DOI:10.20517/2394-5079.2024.33

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49.

[2]	Liu Y.Changes in the epidemiology of hepatocellular carcinoma in Asia.Cancers2022;14:4473.

[3]

Alliance of Chinese Expert Consensus on Neoadjuvant Therapy for Hepatocellular Carcinoma, Committee of Digestive Surgery of Chinese Research Hospital Association, Committee of Liver Cancer, Chinese Anti-Cancer Association. [Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition)].Zhonghua Wai Ke Za Zhi2023;61:1035-45